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Abstract
Background—The pulmonary function measures of forced expiratory volume in one second
(FEV1) and its ratio to forced vital capacity (FVC) are used in the diagnosis and monitoring of
lung diseases and predict cardiovascular mortality in the general population. Genome wide
association studies (GWAS) have identified numerous loci associated with FEV1 and FEV1/FVC
but the causal variants remain uncertain. We hypothesized that novel or rare variants poorly
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tagged by GWAS may explain the significant associations between FEV1/FVC and two genes:
ADAM19 and HTR4.
Methods and Results—We sequenced ADAM19 and its promoter region along with the
approximately 21 kb portion of HTR4 harboring GWAS SNPs for pulmonary function and
analyzed associations with FEV1/FVC among 3,983 participants of European ancestry from
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE). Meta-analysis of
common variants in each region identified statistically significant associations (316 tests, P <
1.58×10−4) with FEV1/FVC for 14 ADAM19 SNPs and 24 HTR4 SNPs. After conditioning on the
sentinel GWAS hit in each gene [ADAM19 rs1422795, minor allele frequency (MAF)=0.33 and
HTR4 rs11168048, MAF=0.40] one SNP remained statistically significant (ADAM19 rs13155908,
MAF = 0.12, P = 1.56×10−4). Analysis of rare variants (MAF < 1%) using Sequence Kernel
Association Test did not identify associations with either region.
Conclusions—Sequencing identified one common variant associated with FEV1/FVC
independently of the sentinel ADAM19 GWAS hit and supports the original HTR4 GWAS
findings. Rare variants do not appear to underlie GWAS associations with pulmonary function for
common variants in ADAM19 and HTR4.
Keywords
genetic polymorphism; lung; population studies; DNA sequencing; Genome Wide Association
Study
Spirometric measures of pulmonary function are easily obtainable and reproducible indices
of the physiologic state of the lung and airways commonly used in clinical medicine. Two
major spirometric measures in clinical practice are the forced expiratory volume in one
second (FEV1) and the ratio of FEV1 to the forced vital capacity (FVC). The FEV1 reflects
airflow obstruction and lung size. Reduction in FEV1 out of proportion to the FVC leads to
a reduced FEV1/FVC ratio. The FEV1/FVC provides an index of airflow obstruction that is
relatively independent of lung size and is the primary criterion for the diagnosis of airway
obstruction and chronic obstructive pulmonary disease (COPD). The FEV1 is used to assess
the severity of the airflow obstruction and monitor the progression of lung diseases
including COPD, asthma, and cystic fibrosis. In addition to its essential role in the diagnosis
and monitoring of respiratory disease, lower pulmonary function has been shown in
numerous studies to be related to increased cardiovascular morbidity and mortality in the
general population, including among nonsmokers without lung disease, and independently
of standard risk factors.1–6
Cross-sectional measures of FEV1 and FEV1/FVC in adults reflect the maximal values
attained at the conclusion of growth and the inevitable decline with age thereafter.
Environmental factors, most notably smoking, influence both maximal growth and the rate
of decline. However, genetics also influence pulmonary function; over 40% of the
variability in pulmonary function has been attributed to genetic factors.7 For decades, the
role of the uncommon genetic deficiency of alpha-1 antitrypsin in reduced pulmonary
function has been appreciated.8 However, other genes involved in pulmonary function
remained elusive prior to the era of genome wide association studies (GWAS). Recent
London et al. Page 2






















GWAS have identified common genetic variants related to FEV1/FVC or FEV1 in at least
27 loci.9–12 Most of these are novel loci not previously implicated in lung pathology. Two of
the novel genes identified for FEV1/FVC are 5-hydroxytryptamine (serotonin) receptor 4
(HTR4) and A Disintegrin And Metallopeptidase Domain 19 (ADAM19).10 Both were
subsequently associated with the clinical phenotypes of airflow obstruction and COPD in
GWAS.13 Interestingly, ADAM19 also plays an essential role in cardiac development14 and
copy number variants have recently been identified in patients with congenital heart
disease.15
While segregation analyses suggest that genetics contribute a substantial portion of the
variability in pulmonary function7, the combined effects of all GWAS-identified loci appear
to explain less than eight percent of the predicted genetic variance.12 The issue of
unexplained heritability in GWAS has been the subject of much recent interest. One of the
explanations invoked is that rare functional variants linked to the common variants
identified by GWAS platforms may be important.16 To this end, in-depth re-sequencing
efforts to systematically follow-up GWAS hits were undertaken in the CHARGE Targeted
Sequencing Study.
We analyzed deep sequencing data for ADAM19 and HTR4 in relation to FEV1/FVC and
FEV1. The goal was to identify whether variants, common or rare, that were not included in




The CHARGE Targeted Sequencing Study includes participants enrolled in three cohorts:
the Atherosclerosis Risk in Communities Study (ARIC), the Cardiovascular Health Study
(CHS), and the Framingham Heart Study (FHS).17 All of the study participants were of
European ancestry and had been included in previous GWAS meta-analysis of the
pulmonary function parameters FEV1 and FEV1/FVC.10 The participants included those
randomly selected from the cohort (the Cohort Random Sample) and those selected for
several different extreme phenotypes (the Phenotype Groups). The Cohort Random Sample
contains approximately 2,000 unrelated individuals representing the distribution of
phenotypes in the general population. The Phenotype Groups contain individuals with
extreme values for at least one of 14 phenotypes; each group has approximately 200
participants (Lin H, et al. Circ Cardiovasc Genet, submitted). The Phenotype Group for
FEV1 and FEV1/FVC included participants selected from the ARIC cohort based on
meeting the following criteria at both visits 1 and 2: FEV1 < 65% predicted and FEV1/FVC
< the lower limit of normal based on NHANES III prediction equations.18 Institutional
review boards at participating centers approved the study and participants provided informed
consent.
London et al. Page 3























In the CHARGE Targeted Sequencing Study, a total of 77 target regions were sequenced to
follow-up selected GWAS findings across multiple phenotypes. Two of these target regions
were selected based on GWAS findings for FEV1/FVC: ADAM19 and HTR4. We analyzed
only these two target regions. For ADAM19 (chr 5), the following regions were submitted
for sequencing based on NCBI build 36: regulatory region (CTCF binding site) between
chromosomal locations 156831095 and 156832298 (hg18) and the gene region +/− 1 kb
(locations 156835890 to 156936346). For HTR4 (chr 5), we submitted for sequencing the 21
kb block containing all of the high signal SNPs from our previous GWAS plus 1 kb up and
downstream (locations 147815802 to 147837526).
The methods of the CHARGE Targeted Sequencing Study have been described fully in a
separate manuscript (Lin H, et al. Circ Cardiovasc Genet, submitted). Briefly,
approximately 2Mb of target regions were captured by a customized NimbleGen Capture
array and sequenced using the ABI SOLiD V4.0 platform. The raw short reads were aligned
to the reference human genome (NCBI Genome Build 36, hg18) by BFAST.19 SAMtools20
was used to pile up aligned reads and call variants with quality filters. The resulting data
were then subjected to quality control procedures. Variants were categorized as known or
novel by comparison with the dbSNP database and the 1000 Genomes project. The
functional impact of identified variants on the encoded proteins was predicted by the
ANNOVAR software package.21
Statistical analysis
Common variants—Due to the study design of CHARGE Targeted Sequencing Study,
participants with extreme phenotypes were over-represented in the sequenced samples
compared with those selected for the random cohort. In order to account for this sampling
bias, we performed analyses with individuals weighted by the inverse of their sampling
probabilities to obtain population-based effect estimates (Lin H, et al. Circ Cardiovasc
Genet, submitted). We tested each common SNP for association with FEV1 and FEV1/FVC
using un-weighted analyses with linear regression models with robust standard error
estimates in ARIC and CHS and linear mixed effects models in FHS to account for family
relatedness. All analyses assumed an additive effect of the alternate allele, and were adjusted
for the same factors as in the original discovery GWAS10: age, sex, standing height,
smoking status (current, past or never-smoker) and pack-years of smoking. Additional
study-specific covariates included recruitment cohort (FHS), recruitment center (ARIC and
CHS) and principal component eigenvalues for population stratification adjustments (ARIC
and FHS). For the weighted association analysis, we used a weighted linear regression in
ARIC and CHS, and weighted linear mixed model in FHS. In order to account for known
GWAS loci, we compared analyses with and without conditioning on the sentinel SNPs in
each GWAS locus from our earlier discovery GWAS of FEV1/FVC: HTR4 rs11168048 and
ADAM19 rs1422795.10 HTR4 rs11168048 gave the smallest P value among SNPs at this
locus in the discovery GWAS.10 ADAM19 rs1422795 was chosen as the sentinel SNP for
conditional analyses because among the several highly correlated (r2 > 0.95) genome-wide
significant SNPs in the discovery GWAS, it is a non-synonymous missense SNP.
Regression models were used to adjust trait values for all covariates in addition to the
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genotype of the sentinel SNP. Residuals from these linear models were then used as the
independent (outcome) variable in the conditional analysis.
The summary statistics (Beta, SE) from each cohort were then meta-analyzed using an
inverse variance meta-analysis approach. We report the p-values from the un-weighted
analysis, and the magnitude of effects from the weighted analysis (Lumley T, Dupuis J, Rice
KM, Barbalic M, Bis JC, Cupples LA, et al. http://stattech.wordpress.fos.auckland.ac.nz/
files/2012/05/design-paper.pdf). In order to account for multiple comparisons, we applied a
Bonferroni correction for the number of common variants (N=316 with MAF>1%)
analyzed. We consider common variants with association p-values less than 1.6×10−4
(0.05/316) as statistically significant.
Rare variants—Single-marker based association analysis has low power for rare variants.
Therefore, we jointly analyzed all rare variants (MAF< 1%, 2166 in ADAM19 and 454 in
HTR4) occurring in each of the two target regions. We tested association of rare variants
with FEV1 and FEV1/FVC using the Sequence Kernel Association Test (SKAT).22 Single
variant summary statistics and genotype covariance matrices were pooled for meta-analysis
(Lumley T, Brody J, Dupuis J, Cupples LA http://stattech.wordpress.fos.auckland.ac.nz/
files/2012/11/skat-meta-paper.pdf). We regarded statistical significance for either of the two
regions tested based on P=0.05/2 = 0.025.
Predicted functional variants
Because the power of SKAT can be sensitive to the inclusion of non-functional variants, we
performed additional analyses restricted to those rare variants predicted to be functional. In
the ADAM19 gene region, variants were restricted to nonsynonymous and splice site SNPs
(61 missense, 1 nonsense and 5 splice site). The region of sequencing around the HTR4 top
GWAS hits fell in a largely intronic region. The HTR4 rare variants most likely to be
functional were selected by utilizing non-coding annotation from ENCODE and TransFac
tracks from the UCSC browser.23 In addition to the four rare exonic variants, SNPs in
ENCODE regions annotated as DNAse hypersensitivity sites or CHiP-Seq transcription
factor binding sites, and variants falling in conserved transcription factor binding motifs
were selected. Applying these criteria, the 454 rare variants in the HTR4 region were refined
to a set of 122 potentially functional variants.
Results
After quality control, valid sequencing data for ADAM19 and HTR4 as well as data on
pulmonary function data were available for 3,983 participants from the three cohorts. This
included 186 selected for severe airflow obstruction, 1,830 selected as a random sample of
cohort participants and 1,967 selected because of extreme values for non-pulmonary
phenotypes. Pulmonary function parameters, age, sex and smoking history of participants
are shown by cohort in Table 1.
For HTR4, sequencing identified a total of 2,630 SNPs including 207 coding SNPs and
2,046 that are novel defined as not present in 1000 Genomes Phase I. For ADAM19, we
identified 3,494 SNPs, including 52 coding SNPs and 2,662 novel SNPs (from Table 2a in
London et al. Page 5






















Lin H, Wang M, Brody JA, Bis JC, Dupuis J, Lumley T, et al. Methods manuscript
submitted to Circ Cardiovasc Genet along with this manuscript).
Common variants
For each of the two regions (ADAM19 and HRT4), in Figure 1, the P values are plotted for
FEV1/FVC and FEV1in relation to the 316 common variants (MAF>1%) before and after
conditioning on the sentinel GWAS SNP from our earlier discovery analysis in each of the
two regions (ADAM19 rs1422795 and HTR4 rs11168048).10 After Bonferroni correction for
316 tests, analysis of individual SNPs identified statistically significant (P<1.58 ×10−4)
associations with FEV1/FVC for 14 SNPs in ADAM19 and 24 SNPs in HTR4, and with
FEV1 for 12 HTR4 SNPs (Table 2). Among the statistically significant SNPs, 11 in HTR4
and 7 in ADAM19 were not included in the original GWAS discovery dataset.10 After
conditioning on the sentinel GWAS SNP in each gene (ADAM19 rs1422795, HTR4
rs11168048), only one SNP surpassed the statistical significance threshold for association
with FEV1/FVC (ADAM19 rs13155908, P = 1.56×10−4). The MAFs for this SNP
rs13155908 (0.12), as well as the other linked SNPs that were significant in the
unconditional analysis (range 0.10–0.17), are much lower than that of the sentinel GWAS
SNP rs1422795 in ADAM19 (0.33). SNP rs13155908 is not in high LD with the sentinel
SNP (r2=0.07) suggesting an independent signal. SNP rs13155908 did not give genome-
wide statistically significant association with FEV1/FVC in the original GWAS discovery
dataset (P= 1.53×10−5).
Rare variants
Meta-analysis of the cohort-specific SKAT estimates combining all variants with MAF <
1% did not provide any evidence for a role of rare variants in either ADAM19 (2166
variants) or HTR4 (454 variants) in relation to either FEV1 or FEV1/FVC (P > 0.95 for all
four analyses). Because the large number of rare variants examined in ADAM19 might dilute
signals from the modest expected number of associated variants, we also created 5 windows
of equal size (433 in windows one to four and 434 in the fifth) and repeated the SKAT meta-
analysis within those. The smallest P value in any window was 0.52.
Potential functional variants
Meta-analysis of the cohort-specific SKAT estimates combining all potential functional rare
variants (62 in ADAM19 and 122 in HTR4) did not reveal any evidence for association with
either FEV1 or FEV1/FVC (P > 0.68 for all four analyses).
Discussion
Spirometry is the most commonly employed assessment of lung function and FEV1/FVC
and FEV1 are critical physiologic measurements in the diagnosis of airflow obstruction and
monitoring of its severity and progression in clinical practice. In previous GWAS9–12, we
have identified a number of novel loci containing common SNPs related to the FEV1/FVC
and FEV1. Two of the novel loci were ADAM19 and HTR4. In subsequent work, we found
evidence that ADAM19 and HTR4 are related to airflow obstruction and COPD.13 In the
current paper, we used targeted sequencing of ADAM19 and HTR4 to address the question of
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whether our previous GWAS findings for FEV1/FVC were due to additional functionally
relevant variants or, alternatively, due to the combined burden of rare alleles not represented
in the earlier GWAS datasets.
Because HTR4 and ADAM19 were only recently identified as novel genes for pulmonary
function and disease in GWAS10–13, they have not been well studied in relation to these
lung phenotypes. However, within the limited published data, there is biologic plausibility
for a role of both genes in lung function and lung pathobiology.
ADAM19 is a member of the “A Disintegrin And Metalloprotease” (ADAM) family of
membrane tethered glycoproteins and is expressed in most tissues including the lung.24 In
lung epithelial cells, TGF-β1 is a prominent mediator of the response to injury, including
fibrosis. ADAM19 was found to be a key responder to stimulation by TGF- β1 in alveolar
epithelial cells and a potentially critical effector of the fibrotic response to injury, an
important step in the pathogenesis of pulmonary fibrosis and other lung diseases. 25
ADAM19 can potentiate pro-inflammatory activity of tumor necrosis factor alpha
(TNFa), 26 a key modulator of airway inflammation. 27 ADAM19 plays a crucial role in
cardiac development; Adam19−/− mice have multiple cardiac developmental defects14 and
ADAM19 copy number variants have recently been identified in patients with congenital
heart disease.15 Thus genetic variation and differential expression of ADAM19 are linked to
both pulmonary and cardiac disease pathogenesis.
HTR4 is a member of the serotoninergic signaling cascade and is expressed in the lung.11
While serotonin (5-HT) is best studied as neurotransmitter, 5-HT signaling plays an
important role in many organ systems.28 In the lung it is involved in control of breathing 28
and smooth muscle contractility29. Serotonin signaling including HTR4 is involved in
human airway inflammation. 30 In a primate asthma model, ozone exposure increased HTR4
expression in the airways31 and this effect was accompanied by enhanced smooth muscle
contractility.32 A recent study designed to follow-up GWAS findings for HTR4 genetic
variants in lung function identified evidence for greater expression of HTR4 in fetal
compared with adult human lung suggesting an important role in lung development33. The
observation that HTR4 genetic variants are related to pulmonary function in both adults and
children further supports a role in lung development.11, 12
Given that family history of cardiovascular disease is common among older adults in the
US, our study sample included a large proportion of participants with a family history of
cardiovascular disease. For example, in the participants in this analysis from the ARIC
cohort, that contributed the largest number to this dataset, 49% reported that one or both
biologic parents had a history of myocardial infarction. Family history of cardiovascular
disease was not associated with airways obstruction [age, sex and smoking adjusted odds
ratio = 1.07, 95% CI 0.79–1.42, P=0.69), a clinically relevant phenotype that showed
association with both SNPs in ADAM19 and HTR413. This result is consistent with previous
epidemiologic findings that reduced pulmonary function is a risk factor for mortality in the
general population independent of traditional risk factors for cardiovascular disease.1–6
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In analyses of all common variants (MAF>1%) in ADAM19 and HTR4 without conditioning
on our sentinel GWAS SNPs, we identified a number of SNPs significantly related to either
FEV1/FVC or FEV1. However these associations appeared to be explained by our previous
GWAS findings because all but one (ADAM19 rs13155908, P= 1.56×10−4, cut-off P value =
1.58×10−4) were no longer significant after adjusting for the sentinel GWAS SNP at each
locus.
There is functional evidence supporting the potential etiologic role of the ADAM19 sentinel
GWAS SNP (rs1422795). It is a nonsynonymous coding SNP resulting in a serine to glycine
substitution. This change is predicted to be “possibly damaging” in Mutation Taster
(.mutationtaster.org/index.html) and PolyPhen-2 34. Evaluation of this SNP in the UCSC
Genome Browser indicates that it is about 6kb upstream of the transcription start site (TSS)
of an ADAM19 transcript variant suggesting that it could be part of the cis-regulatory region
of this transcript. In addition, rs1422795 is close to the beginning of the translation start site
(17 amino acids away) of another ADAM19 transcript variant. Because of this proximity, the
amino acid change could influence the expression of this transcript. Furthermore, rs1422795
is located within a histone H3K27Ac mark—a region associated with regulatory control of
gene expression.
We interrogated the HapMap3 expression Quantitative Trait Loci (eQTL) database of
lymphoblastoid cell lines to assess whether ADAM19 rs13155908, that remained statistically
significant in the conditional analysis, was related to gene expression.35, 36 We found a
significant cis-association between rs13155908 alleles and ADAM19 expression
(Spearman’s rank correlation coefficient= 0.23, P-value= 0.019) in participants of European
ancestry (CEU, n = 109) but not in other ethnicities. The MAF of rs13155908 is very low in
HapMap Asian populations and low in Africans. In contrast the ADAM19 sentinel GWAS
SNP rs1422795 as well as the other top SNP in the original GWAS to which it is closely
linked (rs2277027) were associated with ADAM19 gene expression in the CEU population
(P-value = 0.001 for both SNPs) as well as several other ethnic groups. Furthermore,
rs1422795 (and rs2277027) had significant cis-eQTLs in multiple other tissues including
nerve (P-value = 5.3 × 10−7), adipose (P-value = 1.1 × 10−6), skeletal muscle (P-value = 3.0
× 10−5), whole blood (P-value = 6.7 × 10−6), artery (P-value = 1.2 × 10−4), and suggestive
cis-eQTLs in lung (P-value = 8.0 × 10−4) based on the Genotype-Tissue Expression Portal37.
We did not find other evidence in public databases supporting a functional role for
rs13155908.
For HTR4, our top GWAS SNP rs11168048 is intronic and not predicted to have functional
consequence for the protein. A search of transcription element binding sites (TESS, http://
www.cbil.upenn.edu/cgi-bin/tess/tess) identified this SNP as located within a potential
binding site of the transcription factor ABF1 which is abolished when the T allele is present.
In a subsequent analysis of airflow obstruction, HTR4 rs11168048 gave the smallest P value
among top HTR4 SNPs identified previously by GWAS of pulmonary function10 and in an
analysis limited to smokers, it gave the smallest P value overall among 75 SNP from all
previous GWAS loci for pulmonary function13. Among the high signal SNPs in the current
analysis, 4 fall within regulatory regions identified through overlap with fetal lung DNAse I
hypersensitivity sites.38 Functional annotation of variants in high LD in this region may help
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inform follow-up functional studies to identify the causal variant. We acknowledge that we
limited our sequencing effort to a 21 kb LD block of HTR4 that harbored all of our high
signal SNPs. Thus if our top GWAS SNPs are in high LD with variants outside of this area,
we would not have captured them with our sequencing effort.
SKAT analysis of possibly functional rare variants or of all rare variants did not provide any
evidence for association with FEV1 or FEV1/FVC. While this suggests that our previous
GWAS signals are not explained by rare variants in linkage disequilibrium with them, we
acknowledge that our study and other sequencing efforts tend to be smaller than the
discovery sample sizes and thus will be underpowered for rare variants.
Our analysis of targeted sequencing data for HTR4 gives support for the importance of the
sentinel GWAS hit, although functional evidence in support of this SNP remains sparse. For
ADAM19, the analysis conditioning on the sentinel GWAS SNP suggests the involvement of
an additional SNP implying that there might be more than one causal variant at this locus.
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Regional association plot for common SNPs identified by sequencing in loci investigated for
FEV1/FVC and FEV1. The two loci are ADAM19 on 5q33.3 and HTR4 on 5q.31.1. The P
values for association with the trait (FEV1/FVC or FEV1) from the unconditional analysis
are represented by circles and those from the conditional analysis, accounting for the
sentinel SNP in each locus, are denoted by squares. For each locus, correlations in the
combined study sample between the sentinel SNP from the GWAS and other SNPs
identified by sequencing in the region are depicted in red when 0.8 ≤ r2 < 1, orange when
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0.5 ≤ r2< 0.8, yellow when 0.2 ≤ r2< 0.5 and white when r2< 0.2. Gene annotations are
shown in green, and estimated recombination rates from HapMap are shown in light blue.
The sentinel SNP (rs1422795 for ADAM19 and rs11168048 for HTR4) is annotated with its
unconditional association P value for the trait.
(a) FEV1/FVC, ADAM19 locus
(b) FEV1, ADAM19 locus
(c) FEV1/FVC, HTR4 locus
(d) FEV1, HTR4 locus
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